Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 25 04:00PM ET
20.00
Dollar change
0.00
Percentage change
0.00
%
Index- P/E- EPS (ttm)-3.08 Insider Own35.19% Shs Outstand5.67M Perf Week7.24%
Market Cap165.00M Forward P/E- EPS next Y-2.28 Insider Trans0.00% Shs Float5.35M Perf Month5.65%
Income-4.84M PEG- EPS next Q-0.37 Inst Own34.93% Short Float3.13% Perf Quarter-5.12%
Sales6.36M P/S25.94 EPS this Y-104.07% Inst Trans-2.34% Short Ratio4.68 Perf Half Y195.42%
Book/sh0.86 P/B23.13 EPS next Y-36.06% ROA-36.66% Short Interest0.17M Perf Year277.71%
Cash/sh0.77 P/C25.90 EPS next 5Y- ROE-44.78% 52W Range4.14 - 26.38 Perf YTD162.12%
Dividend Est.- P/FCF- EPS past 5Y73.43% ROI-90.69% 52W High-24.18% Beta1.60
Dividend TTM- Quick Ratio2.90 Sales past 5Y0.00% Gross Margin- 52W Low383.09% ATR (14)2.02
Dividend Ex-Date- Current Ratio2.90 EPS Y/Y TTM84.51% Oper. Margin-157.80% RSI (14)48.48 Volatility15.96% 10.05%
Employees8 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin-76.04% Recom1.00 Target Price55.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q86.46% Payout- Rel Volume3.30 Prev Close20.00
Sales Surprise-0.11% EPS Surprise-5.13% Sales Q/Q- EarningsMay 15 BMO Avg Volume35.83K Price20.00
SMA202.86% SMA50-9.14% SMA20045.61% Trades Volume114,071 Change0.00%
Date Action Analyst Rating Change Price Target Change
Feb-15-24Initiated Canaccord Genuity Buy $50
Nov-17-20Downgrade H.C. Wainwright Buy → Neutral
Mar-21-18Initiated H.C. Wainwright Buy $1.25
Jun-24-24 08:00AM
Jun-11-24 08:00AM
May-20-24 10:09AM
08:00AM
May-15-24 09:54AM
08:00AM Loading…
08:00AM
Apr-03-24 07:00AM
Apr-02-24 07:00AM
Apr-01-24 08:00AM
Mar-28-24 04:05PM
08:30AM
Mar-05-24 08:00AM
Feb-21-24 08:00AM
Feb-20-24 10:22AM
Feb-12-24 08:00AM
08:30AM Loading…
Feb-07-24 08:30AM
07:00AM
Feb-06-24 07:00AM
Feb-05-24 08:00AM
Jan-10-24 07:00AM
Jan-09-24 07:00AM
Jan-05-24 08:00AM
Nov-13-23 07:00AM
Oct-30-23 11:21AM
Oct-25-23 02:50PM
Oct-24-23 07:00AM
Oct-18-23 07:00AM
Oct-05-23 07:00AM
Sep-18-23 10:40AM
Sep-05-23 07:00AM
08:16AM Loading…
Aug-21-23 08:16AM
Aug-15-23 04:01PM
Mar-30-23 07:00AM
Dec-16-22 06:30AM
Dec-05-22 06:30AM
Dec-01-22 07:55AM
Nov-17-22 05:20PM
Nov-14-22 04:01PM
06:30AM
Oct-25-22 06:30AM
Aug-17-22 08:52AM
Aug-11-22 06:48PM
Jul-26-22 07:30AM
Jun-23-22 07:30AM
May-20-22 08:10AM
May-18-22 07:30AM
May-17-22 07:30AM
May-12-22 04:05PM
May-04-22 07:20AM
Apr-18-22 10:42AM
09:20AM
Apr-11-22 07:20AM
Apr-08-22 07:20AM
Apr-06-22 10:15AM
Mar-23-22 10:20AM
Mar-21-22 07:20AM
Mar-09-22 04:56AM
Feb-24-22 07:02AM
Dec-20-21 07:02AM
Dec-16-21 08:59AM
Dec-01-21 07:02AM
Nov-30-21 11:57AM
Nov-29-21 06:27AM
Nov-22-21 07:02AM
Nov-10-21 07:02AM
Oct-28-21 07:30AM
Sep-10-21 07:02AM
Sep-09-21 07:32AM
Sep-08-21 07:32AM
Aug-30-21 07:32AM
Aug-19-21 06:05AM
Aug-11-21 07:32AM
Aug-06-21 10:20AM
Jul-06-21 06:34AM
Jun-30-21 11:14AM
07:35AM
Jun-28-21 08:35AM
Jun-21-21 08:35AM
07:35AM
Jun-18-21 07:35AM
Jun-13-21 06:13PM
May-14-21 08:21AM
May-10-21 10:23AM
07:50AM
07:05AM
Mar-25-21 11:47AM
09:01AM
Mar-18-21 07:05AM
Mar-17-21 07:05AM
Mar-14-21 04:47AM
Mar-04-21 04:05PM
Feb-18-21 04:05PM
Feb-17-21 04:13PM
07:26AM
Feb-16-21 09:18AM
07:35AM
Feb-11-21 10:02PM
05:54PM
Jan-11-21 07:30AM
Dec-04-20 07:20AM
CervoMed, Inc. is a clinical stage biotechnology company. It engages in the business of advancing CNS focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. The company was founded in1995 and is headquartered in Boston, MA.